Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

diazoxide (Rx)Brand and Other Names:Proglycem

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

oral suspension

  • 50mg/mL
more...

Hypoglycemia

Indicated for hypoglycemia due to hyperinsulinism associated with inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy

3 mg/kg/day PO divided q8-12hr initially; typical dose range 3-8 mg/kg/day  

Patients with refractory hypoglycemia may require higher doses

Prader-Willi Syndrome (Orphan)

Orphan designation for diazoxide choline for treatment of Prader-Willi Syndrome

Sponsor

  • Essentialis, Inc; 7915 Corte Cardo; Carlsbad, CA 92009

Dosage Forms & Strengths

oral suspension

  • 50mg/mL
more...

Hypoglycemia

Indicated for hypoglycemia due to hyperinsulinism associated with leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis

Newborn/infant: 10 mg/kg/day PO divided q8hr initially; typical dosage range is 8-15 mg/kg/day PO divided q8-12hr (also see Cautions regarding suspected pulmonary hypertension in newborns and infants)

Children: 3 mg/kg/day PO divided q8hr initially; typical dose range is 3-8 mg/kg/day PO divided q8-12hr 

Dosing Considerations

May be used preoperatively as a temporary measure, and postoperatively, if hypoglycemia persists

Prader-Willi Syndrome (Orphan)

Orphan designation for diazoxide choline in DDRC (crystalline salt of diazoxide in a controlled-release, once-a-day tablet formulation)

Orphan sponsor

  • Essentialis Therapeutics, Inc; 7915 Corte Cardo; Carlsbad, CA 92009
Next

Interactions

Interaction Checker

diazoxide and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            Frequency Not Defined

            Angina

            Cardiac arrest

            Anxiety

            Fever

            Polyneuritis

            CHF

            Hypotension

            Palpitation

            Tachycardia

            Dizziness

            Anorexia

            Abdominal pain

            Constipation

            Diarrhea

            Loss of taste

            Nausea

            Vomiting

            Diabetic ketoacidosis

            Hirsutism

            Scalp hair loss

            Hyperglycemia

            Sodium and fluid retention

            Postmarketing reports

            Pulmonary hypertension in neonates and young infants

            Previous
            Next

            Warnings

            Contraindications

            Hypersensitivity to diazoxide, thiazides, or sulfonamide derivatives

            Cautions

            Use caution in coronary or cerebral insufficiency, DM, extravasation, heart failure (may increase fluid retention), cardiovascular insufficiency, gout, hypotension, hypokalemia, liver disease, renal dysfunction

            Pregnancy

            Compensatory HTN (aortic coarctation, arteriovenous shunt)

            Ineffective in pheochromocytoma

            Nonketotic hyperosmolar coma may occur during treatment; transient cataracts reported

            May displace bilirubin from albumin; use caution in newborns with hyperbilirubinemia

            The antidiuretic property of diazoxide may lead to significant fluid retention, which in patients with compromised cardiac reserve, may precipitate congestive heart failure; the fluid retention will respond to conventional therapy with diuretics

            Concomitantly administered thiazides may potentiate the hyperglycemic and hyperuricemic actions of diazoxide

            Ketoacidosis and nonketotic hyperosmolar coma reported in patients treated with recommended doses usually during intercurrent illness; prompt recognition and treatment essential and prolonged surveillance following the acute episode necessary because of long drug half-life of approximately 30 hours; occurrence of these serious events may be reduced by careful education of patients regarding monitoring urine for sugar and ketones and for prompt reporting of abnormal findings and unusual symptoms to healthcare provider

            Effects of diazoxide on the hematopoietic system and the level of serum uric acid kept in mind; the latter should be considered particularly in patients with hyperuricemia or a history of gout

            Antihypertensive effect of other drugs may be enhanced by diazoxide; should keep this in mind when administering it concomitantly with antihypertensive agents

            Because of protein binding, administration of diazoxide with coumarin or its derivatives may require reduction in dosage of anticoagulants

            Pulmonary hypertension in newborns and infants

            • July 16, 2015: FDA warns clinicians to watch for signs of pulmonary hypertension in infants treated for hypoglycemia with diazoxide and discontinue the drug if symptoms appear
            • There have been 11 cases identified since the drug was approved (1973) and once diazoxide was discontinued, the symptoms resolved
            • Signs of respiratory distress include flaring nostrils, grunting, unusual chest movements, rapid breathing, difficulty feeding, or a bluish tint to the lips or skin
            • Monitoring is especially important for infants who have other risk factors for pulmonary hypertension (eg, meconium aspiration syndrome, respiratory distress syndrome, transient tachypnea of the newborn, pneumonia, sepsis, congenital diaphragmatic hernia, and congenital heart disease)
            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: Excretion in milk unknown; not recommended

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Inhibits pancreatic insulin release resulting increased blood glucose; activates potassium channels

            Relaxes smooth muscle to decrease PVR, increases HR & CO; precise mechanism of hypotensive effect not fully elucidated; antagonism of calcium may be involved

            Pharmacokinetics

            Half-Life: 9-24 hr (children); 24-36 hr (adults), increases in patients with renal impairment

            Duration: varies greatly, may last to 3-12 hr

            Protein binding: 90%

            Metabolism: In liver by oxidation and sulfate conjugation

            Renal Clearance: 4-5 mL/min

            Excretion: urine by glomerular filtration as unchanged drug and metabolites

            Dialyzable: HD: yes, PD: yes; no supplemental dose is required

            Excretion: Urine

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.